Published in

American Society of Hematology, Blood Advances, 18(1), p. 1369-1381, 2017

DOI: 10.1182/bloodadvances.2017006825

Links

Tools

Export citation

Search in Google Scholar

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Key Points Germ line variants in ASXL1 and BIM are strong biomarkers of response to imatinib in chronic phase CML. A combined Sokal risk and ASXL1 and BIM variant model identified a subgroup of patients with the greatest risk of treatment failure.